Update on prevention and screening of cervical cancer

World Journal of Clinical Oncology

Volumn 5, Issue 4, 2014, Pages 744-752

  McGraw, Shaniqua L ^a   Ferrante, Jeanne M ^b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Cancer screening; Cervical cancer; Human papillomavirus; Pap smear; Papillomavirus vaccines

Indexed keywords

EID: 84915788143     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i4.744     Document Type: Article

References (60)

1. Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, Sweetland S. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370: 1609-1621 [PMID: 17993361 DOI: 10.1016/S0140-6736(07)61684-5]
2. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011; 22: 2675-2686 [PMID: 21471563 DOI: 10.1093/annonc/mdr015]
3. Saxena U, Sauvaget C, Sankaranarayanan R. Evidencebased screening, early diagnosis and treatment strategy of cervical cancer for national policy in low- resource countries: example of India. Asian Pac J Cancer Prev 2012; 13: 1699-1703 [PMID: 22799391 DOI: 10.7314/APJCP.2012.13.4.1699]
4. Garland SM. Can cervical cancer be eradicated by prophylactic HPV vaccination? Challenges to vaccine implementation. Indian J Med Res 2009; 130: 311-321 [PMID: 19901440]
5. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007; 7: 11-22 [PMID: 17186016 DOI: 10.1038/nrc2050]
6. Choi YH, Chapman R, Gay N, Jit M. Potential overestimation of HPV vaccine impact due to unmasking of non-vaccine types: quantification using a multi-type mathematical model. Vaccine 2012; 30: 3383-3388 [PMID: 22480925 DOI: 10.1016/j.vaccine.2012.03.065]
7. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19 [PMID: 10451482 DOI: 10.1002/(SICI)1096-9896(199909)189: 13.0.CO; 2-F]
8. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1157-1164 [PMID: 15894666 DOI: 10.1158/1055-9965.EPI-04-0812]
9. Sukasem C, Pairoj W, Saekang N, Pombubpha H, Srichunrasami C, Pongtippan A, Junyangdikul P, Chantratita W. Molecular epidemiology of human papillomavirus genotype in women with high-grade squamous intraepithelial lesion and cervical cancer: will a quadrivalent vaccine be necessary in Thailand? J Med Virol 2011; 83: 119-126 [DOI: 10.1002/jmv.21948]
10. Odida M, de Sanjosé S, Quint W, Bosch XF, Klaustermeier J, Weiderpass E. Human Papillomavirus type distribution in invasive cervical cancer in Uganda. BMC Infect Dis 2008; 8: 85 [PMID: 18577214 DOI: 10.1186/1471-2334-8-85]
11. Sahasrabuddhe VV, Mwanahamuntu MH, Vermund SH, Huh WK, Lyon MD, Stringer JS, Parham GP. Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. Br J Cancer 2007; 96: 1480-1483 [PMID: 17437020]
12. Desruisseau AJ, Schmidt-Grimminger D, Welty E. Epidemiology of HPV in HIV-positive and HIV-negative fertile women in Cameroon, West Africa. Infect Dis Obstet Gynecol 2009; 2009: 810596 [PMID: 20169094 DOI: 10.1155/2009/810596]
13. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26 Suppl 10: K1-16 [PMID: 18847553 DOI: 10.1016/j.vaccine.2008.05.064]
14. Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte- Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2006; 15: 1274-1280 [PMID: 16835323 DOI: 10.1158/1055-9965. EPI-06-0129]
15. Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, Solomon D, Burk R. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100: 513-517 [PMID: 18364507 DOI: 10.1093/jnci/djn044]
16. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-1597 [PMID: 17942872 DOI: 10.1056/NEJMoa073204]
17. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, Koutsky LA. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354: 2645-2654 [PMID: 16790697 DOI: 10.1056/NEJMoa053284]
18. Harper DM, Demars LR. Primary strategies for HPV infection and cervical cancer prevention. Clin Obstet Gynecol 2014; 57: 256-278 [PMID: 24686336]
19. Wen LM, Estcourt CS, Simpson JM, Mindel A. Risk factors for the acquisition of genital warts: are condoms protective? Sex Transm Infect 1999; 75: 312-316 [PMID: 10616354 DOI: 10.1136/sti.75.5.312]
20. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney W, Moscicki AB, Noller KL, Wheeler CM, Ades T, Andrews KS, Doroshenk MK, Kahn KG, Schmidt C, Shafey O, Smith RA, Partridge EE, Garcia F. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007; 57: 7-28 [PMID: 17237032]
21. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez- Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, James M, Vuocolo S, Hesley TM, Barr E. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199: 936-944 [PMID: 19236277 DOI: 10.1086/597309]
22. Schiffman M, Castle PE. The promise of global cervicalcancer prevention. N Engl J Med 2005; 353: 2101-2104 [PMID: 16291978]
23. Centers for Disease Control and Prevention. Recommended adult immunization schedule-United States, 2013. J Midwifery Womens Health 2013; 58: 215-220 [PMID: 23590489 DOI: 10.1111/jmwh]
24. Casper MJ, Carpenter LM. Sex, drugs, and politics: the HPV vaccine for cervical cancer. Sociol Health Illn 2008; 30: 886-899 [PMID: 18761509 DOI: 10.1111/j.1467-9566.2008.01100.x]
25. Leader AE, Weiner JL, Kelly BJ, Hornik RC, Cappella JN. Effects of information framing on human papillomavirus vaccination. J Womens Health (Larchmt) 2009; 18: 225-233 [PMID: 19183094 DOI: 10.1089/jwh.2007.0711]
26. Hull SC, Caplan AL. The case for vaccinating boys against human papillomavirus. Public Health Genomics 2009; 12: 362-367 [PMID: 19684448 DOI: 10.1159/000214926]
27. Calloway C, Jorgensen CM, Saraiya M, Tsui J. A content analysis of news coverage of the HPV vaccine by U.S. newspapers, January 2002-June 2005. J Womens Health (Larchmt) 2006; 15: 803-809 [PMID: 16999634]
28. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 1915-1923 [PMID: 15550200 DOI: 10.3201/eid1011.040222]
29. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943 [PMID: 17494926 DOI: 10.1056/NEJMoa061760]
30. Khan AM, Freeman-Wang T, Pisal N, Singer A. Smoking and multicentric vulval intraepithelial neoplasia. J Obstet Gynaecol 2009; 29: 123-125 [PMID: 19274545]
31. Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health 2012; 12: 370 [PMID: 22621342 DOI: 10.1186/1471-2458-12-370]
32. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012; 62: 147-172 [PMID: 22422631 DOI: 10.3322/caac.21139]
33. Fisher JW, Brundage SI. The challenge of eliminating cervical cancer in the United States: a story of politics, prudishness, and prevention. Women Health 2009; 49: 246-261 [PMID: 19533513 DOI: 10.1080/03630240902915101]
34. Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 156: 880-891, W312 [PMID: 22711081 DOI: 10.7326/0003-4819-156-12-201206190-00424]
35. Peterson NB, Murff HJ, Cui Y, Hargreaves M, Fowke JH. Papanicolaou testing among women in the southern United States. J Womens Health (Larchmt) 2008; 17: 939-946 [PMID: 18582173 DOI: 10.1089/jwh.2007.0576]
36. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008; 111: 167-177 [PMID: 18165406 DOI: 10.1097/01.AOG.0000296488.85807.b3]
37. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Rozendaal L, Heideman DA, Verheijen RH, Bulk S, Verweij W, Snijders PJ, Meijer CJ. HPV DNA testing in populationbased cervical screening (VUSA-Screen study): results and implications. Br J Cancer 2012; 106: 975-981 [PMID: 22251922 DOI: 10.1038/bjc.2011.581]
38. Vetter KM, Geller SE. Moving forward: human papillomavirus vaccination and the prevention of cervical cancer. J Womens Health (Larchmt) 2007; 16: 1258-1268 [PMID: 18001182]
39. Stoler MH, Castle PE, Solomon D, Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP- guided management requires the use of well-validated assays. Am J Clin Pathol 2007; 127: 335-337 [PMID: 17276947]
40. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle- income developing countries. Bull World Health Organ 2001; 79: 954-962 [PMID: 11693978]
41. Sauvaget C, Fayette JM, Muwonge R, Wesley R, Sankaranarayanan R. Accuracy of visual inspection with acetic acid for cervical cancer screening. Int J Gynaecol Obstet 2011; 113: 14-24 [PMID: 21257169 DOI: 10.1016/j.ijgo.2010.10.012]
42. Sahasrabuddhe VV, Bhosale RA, Kavatkar AN, Nagwanshi CA, Joshi SN, Jenkins CA, Shepherd BE, Kelkar RS, Sahay S, Risbud AR, Vermund SH, Mehendale SM. Comparison of visual inspection with acetic acid and cervical cytology to detect high-grade cervical neoplasia among HIV-infected women in India. Int J Cancer 2012; 130: 234-240 [PMID: 21387289 DOI: 10.1002/ijc.25971]
43. Wiwanitkit V. Screening for cervical cancer: which common technique is the most cost-effective choice? Asian Pac J Cancer Prev 2009; 10: 531-532 [PMID: 19640204]
44. Shastri SS, Dinshaw K, Amin G, Goswami S, Patil S, Chinoy R, Kane S, Kelkar R, Muwonge R, Mahé C, Ajit D, Sankaranarayanan R. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bull World Health Organ 2005; 83: 186-194 [PMID: 15798842]
45. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26 Suppl 10: K29-K41 [PMID: 18847555 DOI: 10.1016/j.vaccine.2008.06.019]
46. Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, Weigl B, Zhang WH, Peck RB, Li L, Chen F, Pan QJ, Lorincz AT. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929-936 [PMID: 18805733 DOI: 10.1016/S1470-2045(08)70210-9]
47. Yang HP, Walmer DK, Merisier D, Gage JC, Bell L, Rangwala S, Shrestha N, Kobayashi L, Eder PS, Castle PE. A pilot analytic study of a research-level, lower-cost human papillomavirus 16, 18, and 45 test. J Virol Methods 2011; 176: 112-114 [PMID: 21640138 DOI: 10.1016/j.jviromet.2011.05.024]
48. ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol 2009; 114: 1409-1420 [PMID: 20134296 DOI: 10.1097/AOG.0b013e3181c6f8a4]
49. Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin Number 131: Screening for cervical cancer. Obstet Gynecol 2012; 120: 1222-1238 [PMID: 23090560]
50. Jin XW, Lipold L, McKenzie M, Sikon A. Cervical cancer screening: what's new and what's coming? Cleve Clin J Med 2013; 80: 153-160 [PMID: 23456465 DOI: 10.3949/ccjm.80a.12092]
51. Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2010; 60: 99-119 [PMID: 20228384 DOI: 10.3322/caac.20063]
52. Vijayaraghavan A, Efrusy MB, Mayrand MH, Santas CC, Goggin P. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada. Can J Public Health 2010; 101: 220-225 [PMID: 20737813]
53. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007; 104: 232-246 [PMID: 17084886]
54. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, Cohen C. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52: 342-362 [PMID: 12469763]
55. Rodríguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, Solomon D, Guillén D, Alfaro M, Morales J, Hutchinson M, Katki H, Cheung L, Wacholder S, Burk RD. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010; 102: 315-324 [PMID: 20157096 DOI: 10.1093/jnci/djq001]
56. Fox J, Remington P, Layde P, Klein G. The effect of hysterectomy on the risk of an abnormal screening Papanicolaou test result. Am J Obstet Gynecol 1999; 180: 1104-1109 [PMID: 10329862]
57. Cuzick J, Castañón A, Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br J Cancer 2010; 102: 933-939 [PMID: 20104226 DOI: 10.1038/sj.bjc.6605528]
58. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007; 11: 201-222 [PMID: 17917566]
59. Kjær SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102: 1478-1488 [PMID: 20841605 DOI: 10.1093/jnci/djq356]
60. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-1079 [PMID: 16030305]